Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BeOne Medicines Ltd. - American Depositary Shares (NQ:ONC)

287.92 -2.66 (-0.92%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BeOne Medicines Ltd. - American Depositary Shares

< Previous 1 2 3 4 Next >
News headline image
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 2026
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeOne Medicines Announces Phase 3 HERIZON-GEA Data Published in NEJM and Presented at ASCO 2026
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeOne Medicines to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
From BeOne Medicines Ltd.
Via Business Wire
BEONE MEDICINES LTD-ADR (NASDAQ:ONC) Passes Minervini's SEPA Screen with Strong Technicals and High Growth Momentum ↗
Via Chartmill
BEONE MEDICINES LTD-ADR (NASDAQ:ONC) Passes Minervini Trend Template and Strong Growth Scan ↗
Via Chartmill
News headline image
BeOne Medicines Sets the Pace in Oncology at ASCO and EHA 2026 with 60+ Abstracts
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeOne Medicines Launches One Save Changes Everything, a Global Cancer Care Awareness Campaign with Soccer Legend Tim Howard
From BeOne Medicines Ltd.
Via Business Wire
News headline image
Patient Square Makes a Big Bet on Nektar Pharmaceuticals (NKTR) Purchasing 210,000 Shares ↗
This biotech firm develops immunotherapies for cancer and autoimmune diseases, with several candidates advancing through clinical trials. 
Via The Motley Fool
News headline image
What to Know About This Fund’s $50 Million Exit From Ascendis Pharma ↗
Ascendis Pharma develops long-acting therapies for rare endocrine and pediatric diseases using its proprietary TransCon technology. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Fund Has a $75 Million Bet on a Hair Loss Biotech Stock Up More Than 500% Post-IPO ↗
Veradermics develops novel dermatology treatments, targeting both adult and pediatric markets with a research-driven approach. 
Via The Motley Fool
Topics Initial Public Offering
News headline image
Why This Hedge Fund Added $29 Million to a Cancer Stock Already Up 700% ↗
This clinical-stage biotech develops targeted therapies for RAS/MAPK pathway-driven cancers, addressing hard-to-treat tumor types. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
BeOne Medicines’ BEQALZI™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeOne Medicines Announces First Quarter 2026 Financial Results and Business Updates
From BeOne Medicines Ltd
Via Business Wire
News headline image
U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeOne Medicines to Announce First Quarter 2026 Financial Results on May 6
From BeOne Medicines Ltd.
Via Business Wire
News headline image
This Fintech Stock Is Up 21% in a Year as Profits Surge, but One Fund's Nearly $300 Million Sale Cut Its Stake in Half ↗
Futu Holdings delivers digital brokerage and wealth management solutions to retail and institutional clients across Asia and global markets. 
Via The Motley Fool
News headline image
BeOne Medicines Announces Fourth Quarter and Full Year 2025 Financial Results, Highlighting Global Success of BRUKINSA and Foundational Oncology Leadership
From BeOne Medicines Ltd.
Via Business Wire
News headline image
Investor Buys Up $81 Million in Praxis Stock as Shares Soar Over 300% in One Year ↗
Praxis Precision Medicines develops therapies for neurological and psychiatric disorders, aiming to address unmet needs in the CNS market. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Fund Bet Nearly $40 Million on GRAIL Last Quarter. The Stock Just Plunged Over 50% ↗
GRAIL develops advanced cancer detection technologies, serving healthcare providers and individuals seeking early diagnostic solutions. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
3 Brilliant Growth Stocks to Buy Now and Hold for the Long Term ↗
Don't just buy these stocks. Hold onto them. 
Via The Motley Fool
Topics Artificial Intelligence Earnings
News headline image
HHLR Advisors Fully Exits Baidu as AI Push Tests Its Advertising-Funded Model ↗
Baidu is transitioning from a search-driven advertising company into an AI infrastructure and enterprise cloud provider in China. HHLR’s exit comes as investors weigh whether this transformation will... 
Via The Motley Fool
Topics Artificial Intelligence Economy
News headline image
BeOne Medicines to Present at Upcoming Investor Conferences
From BeOne Medicines Ltd.
Via Business Wire
News headline image
Prediction: These 3 Stocks Will Crush the Market in 2026 ↗
These stocks all have catalysts on the way that could provide great news for investors. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
BeOne Medicines to Announce Fourth Quarter and Full Year 2025 Financial Results on February 26
From BeOne Medicines Ltd.
Via Business Wire
News headline image
3 Stocks to Buy in February ↗
These three stocks appear to be poised for strong performances in 2026. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
BeOne Medicines Highlights Global Oncology Leadership at 44th Annual J.P. Morgan Healthcare Conference
From BeOne Medicines Ltd.
Via Business Wire
News headline image
ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeOne Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BRUKINSA Delivers Landmark 74% 6-Year PFS in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia
From BeOne Medicines Ltd.
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.